Our differentiated core technology pinpoints disease specific antibodies and their preferred antigens thereby providing optimal diagnostic performance.
Focusing powerful molecular evolution technology upon clinical specimens, we are uniquely able to develop diagnostics with unprecedented accuracy that readily integrate into convenient and widely employed clinical testing platforms.
Delivering Superior Antibody Biomarkers
Mar 2014 Serimmune secures license agreement, acquires IP.
Expands discovery capabilities.
Dec 2013 Biomarkers via in vitro evolution
Antibody diagnostics via evolution of peptides technology published in PNAS.